Response to Omalizumab in Solar Urticaria: Report of 3 Cases

We report 3 cases of solar urticaria in which there was no response or limited response to first-line treatments with high-dose H1antihistamines or phototherapy. The patients were then treated with omalizumab. Symptoms improved in 2 patients, whose tolerance to sunlight increased considerably; quality of life clearly improved for 1 of these patients. The third experienced no improvement and developed a mild local reaction to the injected medication. We conclude that omalizumab may offer a potentially safe, useful alternative for patients with solar urticaria who do not respond to conventional therapy.